UBS lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares. The firm updated its forecast to reflect ongoing pressures in academic funding, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics Faces Market Challenges and Uncertainty, Leading to Hold Rating
- 10x Genomics price target lowered to $15 from $18 at Canaccord
- 10X Genomics Faces Mixed Outlook Amid Funding Uncertainties
- 10x Genomics price target lowered to $15 from $18 at Stifel
- 10x Genomics price target lowered to $11 from $15 at TD Cowen
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue